A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
Top Cited Papers
Open Access
- 1 October 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 112 (7), 2667-2674
- https://doi.org/10.1182/blood-2008-03-141481
Abstract
Chronic graft-versus-host disease (cGVHD) is a major limitation of successful hematopoietic cell transplantation. The safety and efficacy of extracorporeal photopheresis (ECP) for 12 to 24 weeks together with standard therapy was compared with standard therapy alone in patients with cutaneous manifestations of cGVHD that could not be adequately controlled by corticosteroid treatment. The primary efficacy end point was a blinded quantitative comparison of percent change from baseline in Total Skin Score (TSS) of 10 body regions at week 12. Ninety-five patients were randomized to either ECP and standard therapy (n = 48) or standard therapy alone (n = 47). The median percentage improvement in TSS at week 12 was 14.5% for the ECP arm and 8.5% for the control arm (P = .48). The proportion of patients who had at least a 50% reduction in steroid dose and at least a 25% decrease from baseline in TSS was 8.3% in the ECP arm at week 12 and 0% in the control arm (P = .04). The nonblinded investigator assessment of skin complete or partial responses revealed a significant improvement in favor of ECP (P < .001). ECP was generally well tolerated. These results suggest that ECP may have a steroid-sparing effect in the treatment of cGVHD. Clinical trials registered at www.ClinicalTrials.gov as NCT00054613.Keywords
This publication has 27 references indexed in Scilit:
- A Single-Center Pilot Validation Study of a New Chronic GVHD Skin Scoring SystemTransplantation and Cellular Therapy, 2007
- Cutaneous Manifestations of Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2006
- Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trialsBone Marrow Transplantation, 2006
- The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalizationTransplant International, 2006
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2006
- Role of extracorporeal photochemotherapy in patients with refractory chronic graft‐versus‐host diseaseBritish Journal of Haematology, 2005
- Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2005
- Development and validation of a scale to measure symptoms of chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2002
- Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialBlood, 2002
- Extracorporeal Photochemotherapy in the Treatment of Severe Graft-Versus-Host DiseaseLeukemia & Lymphoma, 2000